![]() The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.Īs disclosed earlier this year, the CT-01 series of molecular glues are compounds inducing degradation of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Sal-like protein 4 (SALL4) and another undisclosed neo-substrate with essential function in tumorigenesis. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, today announces that it has selected CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC). 10, 2022 (GLOBE NEWSWIRE) - Captor Therapeutics S.A. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.WROCŁAW, Poland, Aug. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Furthermore, he is the founder of Alentis Therapeutics, a Swiss/French biotech company developing novel therapeutics for fibrotic diseases and cancer.Ĭaptor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. He is a member of the US, European, French, and German Liver Societies and an elected member of the American Association of Physicians (AAP). Baumert is Associate Editor of the Journal of Hepatology and serves as a member of the editorial board of several journals in the fields of Gastroenterology, Hepatology, Virology and Infectious Diseases. He has published more than 400 scientific articles in prestigious peer-reviewed journals, such as Cell, Nature, Nature Medicine, Nature Biotechnology, Cell Host & Microbe, PNAS as a senior author and is an inventor on 16 patents and patent applications.ĭr. He has received many awards, including five European Research Council (ERC) awards for the discovery and development of novel approaches to prevent and treat chronic liver disease. The understanding of the molecular mechanisms of liver disease biology enabled his laboratory to uncover novel strategies for the treatment of chronic liver disease and hepatocellular carcinoma. His research focuses on the modelling and discovery of the cell circuits underlying liver disease progressing to cancer. Baumert, MD is Professor of Medicine, head of the Inserm Research Institute for Viral and Liver Diseases (Inserm U1110), director of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Chair of Hepatology at the Center for Digestive Disease and Hepatology at the Strasbourg University Hospitals. If you would like to ask a question during the session, please submit your request to those who are unable to attend, a replay of the webinar will be available here. To register for the webinar, please click here.Ī live question and answer session will also be held. Baumert, MD from the University of Strasbourg on the unmet medical need in HCC and the current landscape of HCC drugs and patient treatments. The event will also feature a presentation by Key Opinion Leader Thomas F. Chief Scientific Officer Michał Walczak, PhD, and Biology Department Director Paweł Dobrzański, PhD, will describe Captor's CT-01 program in hepatocellular carcinoma (HCC) and its potential to redefine the HCC treatment paradigm. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces it will host a virtual Research and Development (R&D) day on Wednesday at 10:00 am EDT (04:00 pm CEST).Ĭaptor's executive management team will discuss the company's broadly applicable Optigrade TM platform and how it allows for the sustainable creation and discovery of TPD drugs. WROCŁAW, Poland, (GLOBE NEWSWIRE) - Captor Therapeutics S.A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |